Loading stock data…
Braveheart Bio, Inc. (BRVE)
$29.41+2.67 (+9.99%)
Market ClosedLast close Sep 8
Braveheart Bio, Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $0 | $0 |
| Gross Profit | — | — |
| Operating Income | -$15.05M↓ | -$5,000 |
| Net Income | -$14.28M↓ | -$99,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.15B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
18.34%
Volume
Today's trading volume
613,229
Recent News
The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’
The past several years saw muted IPO activity, a generally negative signal for market health. But 2026 has reversed that trend. Yes, you can say that the June IPO of SpaceX, the largest ever public offering, which raised over $85 billion in funding for Musk’s private space launch company, has accounted for the bulk of the first half’s IPO activity, but that is only part of the story. Even if you strip out SpaceX, the first half of this year saw new ‘traditional’ initial public offerings generate
Insiders Are Betting Big on These 3 Healthcare Stocks
Insiders are buying shares of Braveheart Bio, BlossomHill Therapeutics and Elanco, three health care stocks with differing risk profiles, analyst ratings, and pipeline catalysts ahead.
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
Jefferies starts biopharma firm Braveheart at Buy after IPO
Investing.com -- Jefferies initiated coverage of Braveheart Bio with a Buy rating and a $48 price target, implying roughly 75% upside from the stock’s prior closing price. The move comes after the company priced its initial public offering (IPO) at $18 per share earlier this month, raising $382.5 million in one of the largest biotech debuts of 2026.
Braveheart Bio (BRVE) Raised $382.5 Million In Its IPO
Braveheart Bio (NasdaqGM: BRVE) completed its IPO and listed on the Nasdaq Global Market, with trading commencing before 11 August 2026. The company was added to the NASDAQ Composite Index shortly after the IPO, bringing the stock into a broad market benchmark. Following the listing and index inclusion, Braveheart Bio filed a large shelf registration to provide flexibility for future capital raises. This kind of rapid move from IPO to index inclusion has drawn attention to founder-led...